Recent Blog Articles
Why is it so challenging to find a primary care physician?
Harvard Health Ad Watch: A new injection treatment for eczema
3 simple swaps for better heart health
I’m too young to have Alzheimer’s disease or dementia, right?
Asking about guns in houses where your child plays
Behavioral weight loss interventions: Do they work in primary care?
Who needs treatment for ocular hypertension?
The popularity of microdosing of psychedelics: What does the science say?
AFM: A scary polio-like illness
When can women with early-stage breast cancer skip radiation after lumpectomy?
Has the new sexual desire drug panned out?
Flibanserin is the first treatment of its kind. But it comes with a steep price tag and severe health risks.
It's now six months since the FDA approved flibanserin (Addyi), which is the first medication for sexual desire disorders. The drug was hailed as a "female Viagra," but is it living up to the hype? "It's not the solution we were hoping for," says Dr. Hope Ricciotti, editor in chief of Harvard Women's Health Watch and an associate professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!